Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Reich K.Gooderham M.Tha?i D.Crowley J.J.Ryan C.Krueger J.G.TSEN-FANG TSAIFlack M.Gu Y.Williams D.A.Thompson E.H.Z.Paul C.2020-10-222020-10-2220190140-6736https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070540421&doi=10.1016%2fS0140-6736%2819%2930952-3&partnerID=40&md5=19d657d0f80700630efe09b71f3a2b61https://scholars.lib.ntu.edu.tw/handle/123456789/517542[SDGs]SDG3Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trialjournal article10.1016/S0140-6736(19)30952-3312809672-s2.0-85070540421